Wegovy Slashes the Risk of Heart Attack and Stroke in a Landmark Trial
WiredSemaglutide is approved for the treatment of type 2 diabetes under the brand name Ozempic and for chronic weight management as Wegovy. The current trial was In patients taking semaglutide, heart rate, blood pressure, cholesterol levels, and a biomarker of inflammation dropped by a larger degree than in those getting a placebo. During the study, 234 patients in the semaglutide group experienced a nonfatal heart attack, and 154 had a nonfatal stroke, compared with 322 and 165 in the placebo group, respectively. Those on semaglutide in the latest trial lost an average of 9.4 percent of their body weight compared with people taking the placebo, who lost less than 1 percent. Jaime Almandoz, a physician who specializes in weight management and metabolism at UT Southwestern Medical Center in Dallas, and who wasn’t part of the trial, says the new data shows that semaglutide provides an added benefit—and may even be better than statins.
History of this topic
Medicine, not miracle drug: Top pharma executive busts weight-loss myths
India Today
Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds
CNN
Medicare can pay for obesity drugs like Wegovy in certain heart patients
Associated Press
Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients
Associated Press
Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients
The Independent
Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds
Associated Press
Obesity drug Wegovy reduces heart attacks and strokes risk by 20%, shows study
Hindustan Times
FDA approves obesity drug that helped people cut weight 15%
The Independent
FDA approves obesity drug that helped people cut weight 15%
LA TimesDiscover Related